{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:13:31Z","timestamp":1780524811664,"version":"3.54.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While ixekizumab (IXE) has demonstrated efficacy in axial spondyloarthritis (axSpA) clinical trials, real-world evidence is limited. This study describes the characteristics and treatment persistence of axSpA patients receiving IXE in routine clinical practice in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study of axSpA patients treated with IXE was carried out in ten hospitals. Demographic, clinical, treatment-related characteristics, persistence and disease activity were collected at baseline, 12, 24 and 52\u2009weeks. Descriptive analysis and Kaplan\u2013Meier methods were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 106 axSpA patients, 69.8% had r-axSpA, 58.5% were male, and 63% had overweight or obesity. Mean (SD) disease duration was 12.8 (12.3) years. 98.1% had received b\/tsDMARDs and 52.5% presented normal C-reactive protein (CRP) levels at baseline. Persistence rates were 99.0, 80.5, and 56.3% at 12, 24, and 52\u2009weeks, respectively. At week 52, 33.3% fewer patients had high\/very high disease activity according to Ankylosing Spondylitis Disease Activity Index (ASDAS-CRP) scores and 18.9% showed an improvement of \u226550% in their Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Exploratory subanalyses showed IXE persistence was not influenced by gender, smoking status, BMI, axSpA clinical form, CRP levels, HLA-B27 status, prior biological (b) or targeted synthetic (ts) DMARD (b\/tsDMARD) or secukinumab. IXE was discontinued by 40 (37.7%) patients during follow-up, mainly due to lack of effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most axSpA patients treated with IXE had long-standing, highly active disease involving multiple domains and prior multiple domains and prior b\/tsDMARDs (b\/tsDMARD) exposure. Despite this, half remained on IXE at 1\u2009year with improved disease activity, highlighting its potential as a treatment option in daily practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1704081","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:22Z","timestamp":1767940822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study)"],"prefix":"10.3389","volume":"12","author":[{"given":"Cristina","family":"Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Concepci\u00f3n","family":"Fito-Manteca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Valero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garc\u00eda-Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Almod\u00f3var","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"D\u00edaz-Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itxaso","family":"Aguirregabiria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"P\u00e9rez-Rambla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"P\u00e9rez-S\u00e1daba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2010.79","article-title":"Pathogenesis of ankylosing spondylitis","volume":"6","author":"Tam","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","year":""},{"key":"ref4","volume-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psori\u00e1sica","year":"2015"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/BOR.0000000000000475","article-title":"Epidemiology of axial spondyloarthritis: an update","volume":"30","author":"Wang","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/RHU.0000000000001575","article-title":"Clinical manifestations and diagnosis of axial spondyloarthritis","volume":"27","author":"Walsh","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref10","first-page":"2475","article-title":"Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health","volume":"33","author":"van Echteld","year":"2006","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.55563\/clinexprheumatol\/lycdc8","article-title":"Social economic costs of ankylosing spondylitis in Spain","volume":"39","author":"Merino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.berh.2015.04.002","article-title":"The impact of ankylosing spondylitis\/axial spondyloarthritis on work productivity","volume":"29","author":"Martindale","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/14737167.2014.957679","article-title":"Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review","volume":"14","author":"Kotsis","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.37803","article-title":"Nonradiographic axial spondyloarthritis: new definition of an old disease?","volume":"65","author":"Sieper","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1759720X17706454","article-title":"Tumor necrosis factor-\u03b1 (TNF\u03b1) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy","volume":"9","author":"Rios Rodriguez","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","article-title":"Psoriasis: rationale for targeting interleukin-17","volume":"167","author":"Girolomoni","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2403935","article-title":"Role of interleukin-(IL-) 17 in the pathogenesis and targeted therapies in spondyloarthropathies","volume":"2018","author":"Chyuan","year":"2018","journal-title":"Mediat Inflamm"},{"key":"ref28","year":"2022"},{"key":"ref29","year":"2021"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/1744666X.2021.1970534","article-title":"Ixekizumab: an IL-17A inhibitor for the treatment of axial spondylarthritis","volume":"17","author":"Harrison","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"ref34","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1016\/S2665-9913(22)00185-0","article-title":"Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis","volume":"4","author":"Maksymowych","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1007\/s12325-022-02132-2","article-title":"Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis through 52 weeks: data from three phase III randomised controlled trials","volume":"39","author":"van der Horst-Bruinsma","year":"2022","journal-title":"Adv Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"815881","DOI":"10.3389\/fmed.2021.815881","article-title":"Association of gender, diagnosis, and obesity with retention rate of secukinumab in spondyloarthropathies: results form a multicenter real-world study","volume":"8","author":"Garc\u00eda-Dorta","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"501872","DOI":"10.1016\/j.reuma.2025.501872","article-title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: real-world data from the BIOBADASER registry","volume":"21","author":"L\u00f3pez-Medina","year":"2025","journal-title":"Reumatol Cl\u00edn"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","article-title":"Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER registry","volume":"9","author":"Moreno-Ramos","year":"2022","journal-title":"Rheumatol Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"rkae018","DOI":"10.1093\/rap\/rkae018","article-title":"Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis","volume":"8","author":"Weddell","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"ref45","volume-title":"Atlas de espondiloartritis axial en Espa\u00f1a: radiograf\u00eda de la enfermedad","author":"Garrido Cumbrera","year":"2017"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e002802","DOI":"10.1136\/rmdopen-2022-002802","article-title":"Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)","volume":"9","author":"Dougados","year":"2023","journal-title":"RMD Open"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e222312","DOI":"10.1001\/jamanetworkopen.2022.2312","article-title":"Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.ard.2025.06.144","article-title":"POS0785\u2005efficacy of ixekizumab in radiographic axial spondyloarthritis patients with normal and elevated CRP: a pooled analysis of phase III clinical trials","volume":"84","author":"Sengupta","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e000802","DOI":"10.1136\/rmdopen-2018-000802","article-title":"Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis","volume":"5","author":"de Winter","year":"2019","journal-title":"RMD Open"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-019-1927-6","article-title":"Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort","volume":"21","author":"L\u00f3pez-Medina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00296-024-05707-0","article-title":"Distinct clinical outcomes linked to peripheral arthritis and dactylitis in axial spondyloarthritis: findings from a retrospective Irish cohort","volume":"44","author":"Kenyon","year":"2024","journal-title":"Rheumatol Int"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"105746","DOI":"10.1016\/j.jbspin.2024.105746","article-title":"In axial spondyloarthritis current smoking is associated with lower prevalence of uveitis and peripheral arthritis in males, but not females","volume":"91","author":"Marsh","year":"2024","journal-title":"Joint Bone Spine"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00296-024-05671-9","article-title":"Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients\u2014a retrospective analysis from the RHADAR network","volume":"44","author":"Strunz","year":"2024","journal-title":"Rheumatol Int"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: a review in ankylosing spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-016-0949-6","article-title":"IL-23\/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients","volume":"18","author":"Milanez","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/biomedicines11051328","article-title":"The Interleukine-17 cytokine family: role in development and progression of spondyloarthritis, current and potential therapeutic inhibitors","volume":"11","author":"Davydova","year":"2023","journal-title":"Biomedicine"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s40744-023-00584-8","article-title":"Persistence and use of ixekizumab in patients with psoriatic arthritis in real-world practice in Spain. The PRO-STIP study","volume":"10","author":"Joven","year":"2023","journal-title":"Rheumatol Ther"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40744-024-00710-0","article-title":"Ixekizumab treatment patterns and health care resource utilization among patients with axial Spondyloarthritis: a retrospective United States claims database study","volume":"11","author":"Danve","year":"2024","journal-title":"Rheumatol Ther"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e005806","DOI":"10.1136\/rmdopen-2025-005806","article-title":"Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study","volume":"11","author":"Jensen","year":"2025","journal-title":"RMD Open"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e002165","DOI":"10.1136\/rmdopen-2021-002165","article-title":"Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST","volume":"8","author":"Braun","year":"2022","journal-title":"RMD Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1704081\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:24Z","timestamp":1767940824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1704081\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":63,"alternative-id":["10.3389\/fmed.2025.1704081"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1704081","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1704081"}}